soroush sohrabi

Peritoneal Cooling May Provide Improved Protection for Uncontrolled Donors After Cardiac Death: An Exploratory Porcine Study

Uncontrolled donation after cardiac death (DCD) renal transplantation relies on rapid establishment of organ preservation interventions. We have developed a model of the uncontrolled DCD, comparing current in situ perfusion (ISP) techniques with additional peritoneal cooling (PC). Ten pigs were killed and subjected to a 2 h ischemia period. The ISP group modeled current DCD protocols. The PC group (PC) modeled current protocols plus PC. Two animals were used as controls and subjected to 2 h of warm ischemia. Core renal temperature and microdialysis markers of ischemia were measured. Preservation interventions began at 30 min, with rapid laparotomy and kidney recovery performed at 2 h, prior to machine perfusion viability testing. The final mean renal temperature achieved in the ISP group was 26.3°C versus 16.9°C in the PC group (p = 0.0001). A significant cryopreservation benefit was suggested by lower peak microdialysate lactate and glycerol levels (ISP vs. PC, p = 0.0003 and 0.0008), and the superiority of the PC group viability criteria (p = 0.0147). This pilot study has demonstrated significant temperature, ischemia protection and viability assessment benefits with the use of supplementary PC. The data suggests a need for further research to determine the potential for reductions in the rates of ischemia‐related clinical phenomena for uncontrolled DCDs.

Dual transplantation of marginal kidneys from nonheart beating donors selected using machine perfusion viability criteria

PURPOSE Viability testing can be used to avoid the transplantation of nonheart beating donor organs that are likely to have primary nonfunction. Such testing also identifies a second group of kidneys which, although unsuitable for solitary transplantation, may be considered for dual transplantation. In kidneys in this group solitary transplants would be unlikely to produce a sufficient glomerular filtration rate to support the recipient. However, if used together as a dual transplant, they have the potential to produce sufficient renal function in 1 patient. MATERIALS AND METHODS The group at our unit has performed 23 dual nonheart beating donor renal transplants from 2003 to date. Using 3 and 12-month post-transplantation recipient glomerular filtration rates as primary end points we compared our dual transplant group with our series of 115 single nonheart beating donor transplants from 1998 to 2006. RESULTS At 3 and 12 months mean glomerular filtration rates in the dual group were 46.2 and 45.5 ml per minute per 1.73 m(2), respectively. These values were not significantly different from the mean glomerular filtration rates of 40.7 and 43.0 ml per minute per 1.73 m(2), respectively, in the single transplant group. CONCLUSIONS We have observed that a subset of nonheart beating donor kidneys that do not satisfy the viability criteria for single organ transplantation may become successful dual organ grafts, thus, avoiding unnecessary organ nonuse and maximizing organ resources.

Porcine Model of Extra-Corporeal Membrane Oxygenation (ECMO) in the Uncontrolled Non-Heart Beating Donor; the Effect on Renal Viability

In response to the novel technique to secure the aorta in donation after cardiac death, described by Mateo et al. [1] in December 2008, we write with a note of caution. We read with great interest the method of employing commercially available cable ties to secure the aorta, for organ perfusion in DCD donors. The technique aims to create a simple, rapid technique to secure an aortic cannula and thereby minimize the warm ischaemic time. After mobilizing and isolating the aorta in standard fashion, the cable tie is passed around a section of the aorta, proximal to the planned site of arteriotomy. Once the aortotomy is performed and the cannula has been placed in the desired position, the cable tie is tightened to secure the cannula in place. The benefits of this technique, described by Mateo, seemed clear. It is rapid, secure and simple. It has the added benefit of secure control of atherosclerotic vessels – where nylon ties have been noted to fracture vessel walls. We decided to undertake a trial of this technique in our current research model assessing the benefits of extra-corporeal membrane oxygenation (ECMO), over combined intra-vascular and -peritoneal cooling in a porcine model of donation-after-cardiac death. In both comparison groups we cannulated the aorta and vena cava at an initial laparotomy. The aortic cannula was employed to administer the ECMO or arterial cooling and flush. In an alteration to the technique employed by Mateo, we used a commercially available cable tie gun (Fig. 1) to secure the tie and tighten it down. Once the tie had been positioned around the aorta, the tip of the tie was passed through the ratcheted head and the tie loosely tightened down around the vessel. After performing the aortotomy and positioning the cannula, the gun was used to rapidly and securely tighten the cable-tie around the vessel and cannula (Fig. 2). The loose end of the tie can be cut when desired by firing an additional trigger on the gun. The major drawback of this technique, as we later discovered, is that use of the cable tie gun leads to a loss in tactile feedback. The cable tie can therefore be easily over tightened and constrict the cannula within the aorta. On commencing our ECMO bypass circuit, we immediFigure 2 Application of cable-tie to secure the aortic cannula, using a cable-tie gun. Figure 1 Commercially available cable-tie gun.

Poor Perfusion of Retrieved Kidneys from Non-Heart Beating Donors: The Impact of Machine Perfusion

In response to the novel technique to secure the aorta in donation after cardiac death, described by Mateo et al. [1] in December 2008, we write with a note of caution. We read with great interest the method of employing commercially available cable ties to secure the aorta, for organ perfusion in DCD donors. The technique aims to create a simple, rapid technique to secure an aortic cannula and thereby minimize the warm ischaemic time. After mobilizing and isolating the aorta in standard fashion, the cable tie is passed around a section of the aorta, proximal to the planned site of arteriotomy. Once the aortotomy is performed and the cannula has been placed in the desired position, the cable tie is tightened to secure the cannula in place. The benefits of this technique, described by Mateo, seemed clear. It is rapid, secure and simple. It has the added benefit of secure control of atherosclerotic vessels – where nylon ties have been noted to fracture vessel walls. We decided to undertake a trial of this technique in our current research model assessing the benefits of extra-corporeal membrane oxygenation (ECMO), over combined intra-vascular and -peritoneal cooling in a porcine model of donation-after-cardiac death. In both comparison groups we cannulated the aorta and vena cava at an initial laparotomy. The aortic cannula was employed to administer the ECMO or arterial cooling and flush. In an alteration to the technique employed by Mateo, we used a commercially available cable tie gun (Fig. 1) to secure the tie and tighten it down. Once the tie had been positioned around the aorta, the tip of the tie was passed through the ratcheted head and the tie loosely tightened down around the vessel. After performing the aortotomy and positioning the cannula, the gun was used to rapidly and securely tighten the cable-tie around the vessel and cannula (Fig. 2). The loose end of the tie can be cut when desired by firing an additional trigger on the gun. The major drawback of this technique, as we later discovered, is that use of the cable tie gun leads to a loss in tactile feedback. The cable tie can therefore be easily over tightened and constrict the cannula within the aorta. On commencing our ECMO bypass circuit, we immediFigure 2 Application of cable-tie to secure the aortic cannula, using a cable-tie gun. Figure 1 Commercially available cable-tie gun.

Outcomes of damaged donor livers following liver transplantation

1 A Novel siRNA-Containing Solution Protecting Donor Organs in Heart Transplantation. Xiufen Zheng,1 Dameng Lian,1 Mu Li,1 Xusheng Zhang,1 Mahdieh Khoshniat,3 Hongtao Sun,1 Weihua Liu,1 Jifu Jiang,1 Dong Chen,1 Costin Vladau,1 Motohiko Suzuki,1 James C. Lacefi eld,3 Bertha Carcia,1,2 Anthony M. Jevnikar,1,2,3 Wei-Ping Min.1,2,3 1Department of Surgery, Pathology, and Microbiology & Immunology, University of Western Ontario, London, ON, Canada; 2Multi-Organ Transplant Program, London Health Sciences Centre, London, ON, Canada; 3Robarts Research Institute, London, ON, Canada. Background: Ischemia-reperfusion (I/R) injury occurs in organ transplantation. We hypothesize that siRNA can effectively suppress infl ammatory, apoptosis and complement genes which contribute to I/R injury. This study was designed to develop a novel siRNA-containing preservation solution, which offers an alternative for protection of donor organs. Methods: Multiple siRNAs that specifi cally target TNFα, Fas, and C3 genes were prepared using our newly-developed bio-synthesis method. Heart grafts from BALB/c mice were preserved in UW solution (control) or siRNA-containing UW solution (siRNA solution) at 4°C for 48 hrs, and subsequently transplanted into syngeneic BALB/c mice. Cardiac functions were quantitatively assessed by High Frequency Ultrasound. The I/R injury was assessed by immunohistochemistry. Results: After 48 hrs preservation in the siRNA solution, the expressions of TNFα, Fas, and C3 genes in the grafts were inhibited at mRNA and protein levels detected by qPCR and immunoblot. Using siRNA solution preserved organ as donor, the graft survival was signifi cantly prolonged in heart transplantation. While siRNA solution-treated heart grafts retained strong heartbeat up to the end point of observation (>70 days), the control grafts lost function within 7 days. In addition, an improved cardiac function was observed in the graft preserved in siRNA solution. Grafts treated by siRNA solution displayed normal function, whereas grafts preserved in control solution showed dysfunction as detected by ultrasound scanning. The protection of graft by siRNA solution is associated with prevention of I/R injury. siRNA solution-treated organs exhibited almost normal histological structures, less neutrophil and lymphocyte infi ltration as compared with control solution-treated organs. Furthermore, siRNA solution prevented apoptosis and necrosis of cardiac tissues. Conclusions: This is the fi rst demonstration of a novel siRNA solution that can prevent cardiac I/R injury, protect cardiac function, and prolong graft survival in heart transplantation, implying a signifi cant and potential application in clinic. Abstract# 2 The Long-Term Evaluation of HLA-Mismatched Combined Kidney and Bone Marrow Transplant Recipients after Complete Withdrawal of Immunosuppression. Tatsuo Kawai,1 David H. Sachs,2 Thomas Spitzer,3 Nina Tolkoff-Rubin,1 Susan Saidman,4 Winfred Williams,1 Bimalangshu Dey,3 Nelson Goes,1 Dicken Ko,1 Waichi Wong,1 Robert B. Colvin,4 Megan Sykes,2 A. Benedict Cosimi.1 1Transplantation Unit, Massachusetts General Hospital, Boston, MA; 2Trasnplant Biology Research Center, MGH, Charlestown, MA; 3Bone Marrow Transplant Unit, MGH, Boston, MA; 4Pathology, MGH, Boston, MA; 5this Study was Performed in Partnership with Immune Tolerance Network. BACKGROUND: Induction of allograft tolerance has been the ultimate goal in organ transplantation. METHODS: Five subjects with ESRD received combined kidney and bone marrow transplantation (CKBMT) from HLA mismatched donors. The preparative regimen consisted of cyclophosphamide, thymic irradiation, anti-CD2 mAb and a 9-14 months course of a calcineurin inhibitor. Two subjects also received two doses of antiCD20 mAb prior to transplant. RESULTS: All recipients developed transient mixed chimerism without GVHD.Complete withdrawal of immunosuppressive medication was achieved in 4/5 recipients with current immunosuppression-free survival exceeding 3.2, 2 The Long-Term Evaluation of HLA-Mismatched Combined Kidney and Bone Marrow Transplant Recipients after Complete Withdrawal of Immunosuppression. Tatsuo Kawai,1 David H. Sachs,2 Thomas Spitzer,3 Nina Tolkoff-Rubin,1 Susan Saidman,4 Winfred Williams,1 Bimalangshu Dey,3 Nelson Goes,1 Dicken Ko,1 Waichi Wong,1 Robert B. Colvin,4 Megan Sykes,2 A. Benedict Cosimi.1 1Transplantation Unit, Massachusetts General Hospital, Boston, MA; 2Trasnplant Biology Research Center, MGH, Charlestown, MA; 3Bone Marrow Transplant Unit, MGH, Boston, MA; 4Pathology, MGH, Boston, MA; 5this Study was Performed in Partnership with Immune Tolerance Network. BACKGROUND: Induction of allograft tolerance has been the ultimate goal in organ transplantation. METHODS: Five subjects with ESRD received combined kidney and bone marrow transplantation (CKBMT) from HLA mismatched donors. The preparative regimen consisted of cyclophosphamide, thymic irradiation, anti-CD2 mAb and a 9-14 months course of a calcineurin inhibitor. Two subjects also received two doses of antiCD20 mAb prior to transplant. RESULTS: All recipients developed transient mixed chimerism without GVHD.Complete withdrawal of immunosuppressive medication was achieved in 4/5 recipients with current immunosuppression-free survival exceeding 3.2, 2.5, 1.1 and 0.2 years. A recipient rejected his kidney allograft on day 10. (1) The most recent creatinine/GFR of these 4 subjects were 1.2/61, 1.6/75, 1.6/96 (by renogram), 1.8/71 ml/min, respectively. (2)Although Subjects 2 and 5 initially developed anti-donor antibodies (ADA), both recipients lost ADA by 10th and 3rd month, respectively. Subject 4 developed post-transplant de novo anti-class II ADA one month after discontinuation of his immunosuppression, but without any functional derangements. (3) Subjects 1, 2 and 4 showed donor specifi c hyporesponsiveness in CML and MLR after nine months. (4) Allograft biopsies taken at 3 years from Subjects 1 and 2 revealed normal glomerulus, no tubulitis and no vasculopathy by light and electron microscopic examination with no C4d staining. Biopsy taken at 1.5 years from Subject 4 showed positive C4d deposition with no changes diagnostic of rejection. A most recent biopsy taken from Subject 5 on day 243 showed no rejection. (5) In Subject 1, extensive warts due to human polyoma virus existed before transplantation, but it disappeared after discontinuation of immunosuppression. All four patients show no hypertension, no DM, no abnormal lipid profi les. CONCLUSIONS: Renal allograft function of CKBMT recipients has been stable up to 3 years after complete withdrawal of their immunosuppression. Abstract# 3 A Novel Human Anti-CD40 Monoclonal Antibody, 4D11, for Kidney Transplantation in Cynomolgus Monkeys, Effect of Induction and Maintenance Therapy. Takeshi Aoyagi,1 Tomomi Suzuki,1 Atsushi Sugitani,2 Atsushi Imai,1 Motohiro Uno,1 Ryoichi Goto,1 Kenichiro Yamashita,1 Toru Miura,3 Nobuaki Takahashi,3 Tomoo Itoh,4 Hiroyuki Furukawa,1 Satoru Todo.1 11st Dept of Surgery, Hokkaido Univ., Sapporo, Hokkaido, Japan; 21st Dept of Surgery, Kyusyu Univ., Hakata, Fukuoka, Japan; 3Kirin Brewery Co., Ltd, Takasaki, Gunma, Japan; 4Dept of Surgical Pathology, Hokkaido Univ. Hospital, Sapporo, Hokkaido, Japan. Background/Aim: We have previously demonstrated that a novel human anti-CD40 monoclonal antibody (mAb), 4D11, markedly prolongs renal allograft survival in cynomolgus monkeys. In this study, we evaluated the effect of induction and maintenance therapy using 4D11. Methods: Twenty-four monkey renal transplants were divided into three groups: no treatment (Control), induction (Group A) and maintenance (Group B) treatments. Groups A and B were further subdivided according to the dose of 4D11 (n=3 each). The 4D11 was given intravenously on days 0, 4, 7, 11 and 14 for the induction therapy. In the group B, a half of the initial dose was given weekly thereafter until day 180. Graft survival, graft histology, anti-4D11 and anti-donor antibodies were examined. Results: Treatment Group 4D11 (mg/kg) Graft survival (days) Mean (days) Cause of death No treatment Control 5, 6, 7 6.0 AR, AR, AR Induction A-I 5 >96, 79, 75 83.3 Alive, AR, AR A-II 10 >200, 107, 92 133.0 Alive, CAN, AR A-III 20 169, 105, 90 121.3 AR, AR, AR Maintenance B-I 1 80, 79, 10 56.3 AR, AR, AR B-II 5 >202, 98, 44 114.3 Alive, AR, AR B-III 10 374, 253, 27 218.3 AR, AR, UTI B-IV 20 216, 169, 153 179.3 CAN, AR, CAN AR: Acute rejection, CAN: Chronic allograft nephropathy, UTI: Urinary tract infection No adverse events were observed. Graft survival was markedly prolonged by the induction treatment, which was further extended by the maintenance treatment. While graft biopsies revealed grade II or III rejection in the control, majority of those from groups A and B at 1 month post-transplantation showed only a borderline change. Anti 4D11-Ab was detected only in group A-III after drug cessation. In addition, animals receiving induction treatment and those given maintenance treatment with high doses of 4D11 did not develop anti-donor Ab unless the treatment was discontinued. Conclusion: 4D11 exhibited potent immunosuppressive effect on renal allograft survival both by induction and maintenance treatments. Besides, anti-drug and anti-donor antibody productions were effectively suppressed by 4D11. Abstract# 4 Pre-Transplant (Tx) Donor-Specifi c B Cells in Highly Sensitized Patients (HS), Detected by Intracellular Cytokine Flow Cytometry (CFC) Predict Antibody Mediated Rejection (AMR). Mieko Toyoda,1 Andy Pao,1 Ashley Vo,1 Marina Lukovsky,1 Raju Radha,1 Tetsu Sado,1 Lara Baden,1 Anna Petrosyan,1 Stanley C. Jordan.1 1Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA. Background: Intravenous immunoglobulin treatment (IVIG-Rx) reduces panel reactive antibodies and crossmatch (CMX) positivity, facilitating CMX(-) kidney Tx in HS. However, high rates of allograft rejec